Cargando…

PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects

The phospatidylinositol-3 kinase (PI3K) pathway is a crucial intracellular signaling pathway which is mutated or amplified in a wide variety of cancers including breast, gastric, ovarian, colorectal, prostate, glioblastoma and endometrial cancers. PI3K signaling plays an important role in cancer cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mishra, Rosalin, Patel, Hima, Alanazi, Samar, Kilroy, Mary Kate, Garrett, Joan T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037248/ https://www.ncbi.nlm.nih.gov/pubmed/33801659 http://dx.doi.org/10.3390/ijms22073464

Ejemplares similares

HER3 Alterations in Cancer and Potential Clinical Implications
por: Kilroy, Mary Kate, et al.
Publicado: (2022)

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2021)

RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells
por: Patel, Hima, et al.
Publicado: (2023)

HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers
por: Alanazi, Samar M., et al.
Publicado: (2023)

Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth
por: Mishra, Rosalin, et al.
Publicado: (2021)

HER3 signaling and targeted therapy in cancer
por: Mishra, Rosalin, et al.
Publicado: (2018)

BRAF Mutant Melanoma Adjusts to BRAF/MEK Inhibitors via Dependence on Increased Antioxidant SOD2 and Increased Reactive Oxygen Species Levels
por: Yuan, Long, et al.
Publicado: (2020)

Current Advances in the Treatment of BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2020)

Genomic alterations of ERBB receptors in cancer: clinical implications
por: Mishra, Rosalin, et al.
Publicado: (2017)

Activating HER3 mutations in breast cancer
por: Mishra, Rosalin, et al.
Publicado: (2018)

Utilization of Reactive Oxygen Species Targeted Therapy to Prolong the Efficacy of BRAF Inhibitors in Melanoma
por: Yuan, Long, et al.
Publicado: (2018)

Will PI3K pathway inhibitors be effective as single agents in patients with cancer?
por: Garrett, Joan T., et al.
Publicado: (2011)

Erratum: Will PI3K pathway inhibitors be effective as single agents in patients with cancer?
por: Garrett, Joan T., et al.
Publicado: (2018)

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design
por: Massacesi, Cristian, et al.
Publicado: (2016)

Challenges in the clinical development of PI3K inhibitors
por: Massacesi, Cristian, et al.
Publicado: (2013)

Clinical implications of Girdin and PI3K protein expression in breast cancer
por: JIN, FENG, et al.
Publicado: (2013)

Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors
por: Rewcastle, Gordon W, et al.
Publicado: (2017)

PI3Kα Inhibitors That Inhibit Metastasis
por: Schmidt-Kittler, Oleg, et al.
Publicado: (2010)

PI3K inhibitors in inflammation, autoimmunity and cancer
por: Stark, Anne-Katrien, et al.
Publicado: (2015)

Phytochemicals and PI3K Inhibitors in Cancer—An Insight
por: Suvarna, Vasanti, et al.
Publicado: (2017)

PI3K inhibitors: review and new strategies
por: Zhang, Mingzhen, et al.
Publicado: (2020)

PI3K inhibitors in thrombosis and cardiovascular disease
por: Durrant, Tom N., et al.
Publicado: (2020)

Development and safety of PI3K inhibitors in cancer
por: Yu, Miaomiao, et al.
Publicado: (2023)

B $\to \pi \pi$, New Physics in B $\to \pi$K and Implications for Rare K and B Decays
por: Buras, Andrzej J., et al.
Publicado: (2003)

Roles of PI3K pan-inhibitors and PI3K-δ inhibitors in allergic lung inflammation: a systematic review and meta-analysis
por: Kim, Jong Seung, et al.
Publicado: (2020)

Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib
por: Till, Kathleen J., et al.
Publicado: (2023)

New Aspects of $B\to\pi\pi, \pi K$ and their Implications for Rare Decays
por: Buras, Andrzej J., et al.
Publicado: (2005)

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
por: Akinleye, Akintunde, et al.
Publicado: (2013)

Structural Determinants of Isoform Selectivity in PI3K Inhibitors
por: Miller, Michelle S., et al.
Publicado: (2019)

Efficacy of PI3K inhibitors in advanced breast cancer
por: Verret, B, et al.
Publicado: (2019)

The present and future of PI3K inhibitors for cancer therapy
por: Castel, Pau, et al.
Publicado: (2021)

PI3k Inhibitors in NHL and CLL: An Unfulfilled Promise
por: Bou Zeid, Naji, et al.
Publicado: (2023)

Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors
por: Brandão, M, et al.
Publicado: (2019)

PI3K mutations in breast cancer: prognostic and therapeutic implications
por: Mukohara, Toru
Publicado: (2015)

Convergent loss of PTEN leads to clinical resistance to a PI3Kα inhibitor
por: Juric, Dejan, et al.
Publicado: (2014)

RF07 | PSUN356 Synergistic Combination of HSP90 and PI3K inhibitors in Adrenocortical Cancer
por: Mishra, Prachi, et al.
Publicado: (2022)

A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome
por: Rao, V. Koneti, et al.
Publicado: (2023)

The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases
por: Banham-Hall, Edward, et al.
Publicado: (2012)

Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer
por: Weigelt, Britta, et al.
Publicado: (2012)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_i8h7i933bcmeb9d680d87mi9h9